Blood Biomarkers, Latest Treatments, and Brain Health Insights
Alzheimer’s disease is one of the most talked-about—and misunderstood—neurological conditions today. With constant news headlines, social media discussions, and emerging research, patients and families are often left confused about what is true, what is still being studied, and what actually helps.
In a recent episode of KHON2’s Working for Hawaii: Unscripted, Dr. Kore Liow, neurologist and Alzheimer’s expert, addressed common myths, misinformation, and controversies surrounding Alzheimer’s disease. The discussion focused on three major areas: blood biomarkers, current treatments, and brain health strategies, including insights from the US POINTER Study.
Common Myths About Alzheimer’s Disease
One of the biggest challenges in Alzheimer’s care is misinformation. Many people believe Alzheimer’s is a normal part of aging or that nothing can be done once symptoms begin. These assumptions can delay diagnosis, discourage early evaluation, and prevent patients from accessing helpful interventions.
The discussion emphasized that Alzheimer’s disease is a neurological condition, not a normal aging process, and that early identification plays a critical role in care planning and symptom management.
Understanding Alzheimer’s Blood Biomarkers
Blood biomarkers have become a major topic of discussion in Alzheimer’s research and media coverage. While these tests show promise, there is confusion about what they can and cannot do.
Dr. Liow explained that blood biomarkers are emerging tools designed to help identify biological changes associated with Alzheimer’s disease. However, they are not standalone diagnostic tests and should be interpreted within a broader clinical context that includes medical history, cognitive evaluation, and imaging when appropriate.
Clear communication is essential so patients understand that biomarkers are part of an evolving field and not definitive answers on their own.
Addressing Controversies Around Alzheimer’s Treatments
Another area of confusion involves new and emerging treatments. Media coverage can sometimes create unrealistic expectations or misunderstandings about what treatments can achieve.
The conversation highlighted the importance of:
- Understanding the purpose and limitations of current therapies
- Recognizing that treatment decisions must be individualized
- Emphasizing careful medical guidance when considering new options
Treatments may help slow disease progression or manage symptoms, but they are not cures. Ongoing research continues to refine how and when these treatments are most effective.
Brain Health and Prevention: Lessons from the US POINTER Study
Brain health was a key part of the discussion, including findings from the US POINTER Study, which focuses on lifestyle-based approaches to cognitive health.
The study reinforces that brain health is influenced by multiple factors, including daily habits and overall wellness. Rather than relying on a single solution, a comprehensive approach to brain health is encouraged.
This perspective empowers individuals by emphasizing proactive steps that support cognitive function over time.
Why Accurate Information Matters
Misinformation can create fear, delay care, and undermine trust in medical guidance. Educational conversations like this one help patients, caregivers, and the public better understand:
- What Alzheimer’s disease is—and is not
- How new tools like blood biomarkers should be viewed
- Why informed medical guidance is essential
- The value of ongoing research and lifestyle-focused brain health strategies
Final Thoughts
Alzheimer’s disease is complex, but clarity matters. By addressing myths, explaining evolving research responsibly, and promoting evidence-based brain health strategies, patients and families are better equipped to make informed decisions.
Ongoing education, thoughtful research, and open conversations with medical professionals remain essential as science continues to advance.
